XTX202
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor
Trial Timeline
Jan 18, 2022 → Mar 25, 2025
NCT ID
NCT05052268About XTX202
XTX202 is a phase 1/2 stage product being developed by Xilio Therapeutics for Advanced Solid Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT05052268. Target conditions include Advanced Solid Tumor.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05052268 | Phase 1/2 | Completed |
Competing Products
20 competing products in Advanced Solid Tumor